SecBot SecBot

QURE

uniQure N.V.
Nasdaq· Pharmaceutical Preparations· CIK 0001590560 Biotech & Drug Discovery
$23.81 −0.82 (−3.33%)
Nov 13 4:00 PM ET · prev $24.63
Market cap
$1.7B
Small cap
Consensus
Buy
85% Buy or better · 20 analysts
Median target
🔒 Subscribers only
1 year
−21.5%
from $30.33 · Nov 17
30 days
+7.3%
from $22.20
52-week range
$9.03–51.05
−53% from high · low Mar 3
Avg volume 20D
1.97M
Nov 2 spike 6.44M
Short interest
8.51M
≈12.1% of shares · −2.5%
Days to cover
6.4
at average volume
Insider net
−$16.7M
0 buyers · 11 sellers · since Jun 10
New fund stakes
1
Q3 2026 13F · 0 exits
Filing reports
35
analyzed by SecBot
SecBot read BULLISH 7 reports · 90 days
Balance 0 bearish · 4 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 7/7 ·Next FDA decision date, May 1, 2027

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    11 insiders sold $16.7M.

  • InstitutionsBULLISH

    Q3 2026: 22 added (1 new), 12 trimmed or exited.

  • AnalystsBULLISH

    17 of 20 rate it Buy or better.

  • Short sellersSTEADY

    Short interest −2.5% to 8.51M shares. 6.4 days to cover, ≈12.1% of shares.

  • TrendRANGE

    19% below its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Nov 2.

Who's buying

13F· Q3 2026
1
new positions
0
exits
FundMoveSharesValue
MORGAN STANLEYADD1,933,936$46.7M
Aberdeen Group plcTRIM1,915,227$46.3M
JANE STREET GROUP, LLCTRIM968,094$23.4M
FMR LLCTRIM903,077$21.8M
MARSHALL WACE, LLPADD576,162$13.9M
CITIGROUP INCDOUBLED554,031$13.4M
HRT FINANCIAL LPDOUBLED539,513$13.0M
UBS Group AGTRIM331,801$8.0M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

20 analysts
Buy 85% rate it Buy or better
Strong Buy8Buy9Hold3Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Oct 5, 2026Barclays
DOWNGRADE
DOWNGRADEEqual-Weight
Oct 2, 2026RBC Capital
MAINTAIN
MAINTAINOutperform
Sep 30, 2026Goldman Sachs
MAINTAIN
MAINTAINNeutral
Jul 30, 2026Wells Fargo
MAINTAIN
MAINTAINOverweight
Jul 30, 2026Wolfe Research
UPGRADE
UPGRADEOutperform
Jul 30, 2026Barclays
MAINTAIN
MAINTAINOverweight

Washington

Corporate Lobbying

5 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Insider ledger

Form 4
$0
bought · 0 insiders
$16.7M
sold · 11 insiders
DateInsiderTypeValue
Nov 6, 2026
Meek David D.
Director
Nov 6, 2026
SELL$192.9K
Oct 30, 2026
Abi-Saab Walid
Chief Medical Officer
Oct 30, 2026
AWARD18,750 sh
Jul 2, 2026
Kapusta Matthew C
CEO, Managing Director
Jul 2, 2026
SELL$194.5K
Jul 2, 2026
Kapusta Matthew C
CEO, Managing Director
Jul 2, 2026
SELL$408.8K
Jul 2, 2026
Kapusta Matthew C
CEO, Managing Director
Jul 2, 2026
SELL$348.8K
Jul 2, 2026
Kapusta Matthew C
CEO, Managing Director
Jul 2, 2026
EXERCISE$408.8K
Jun 30, 2026
Kaye Jack
Director
Jun 30, 2026
SELL$190.9K
Jun 30, 2026
Abi-Saab Walid
Chief Medical Officer
Jun 30, 2026
SELL$464.6K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Reddit
Recent posts
All social signals and their track records

Short side

FINRA· Oct 30, 2026
8,507,475
shares short
-2.5%
vs prior settlement
6.4
days to cover
≈12.1%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 6, 2026 SEC
Director David D. Meek filed a Form 144 notice of intent to sell 9,080 ordinary shares of uniQure N.V., valued at…
144 · Impact 2/10
Nov 6, 2026 Insider
Meek David D. sold 9,080 shares
Director @ $21.25 ($192.9K)
Nov 4, 2026 SEC
The headline event is the FDA granting Priority Review of the BLA for AMT-130 (ifezuntirgene inilparvovec) in…
8-K · Impact 7/10
Nov 4, 2026 SEC
The headline event is the FDA's acceptance of the BLA for AMT-130 in Huntington's disease under Priority Review, with…
PRESS-RELEASE · Impact 6/10
Nov 4, 2026 Earnings
uniQure Announces Third Quarter 2026 Financial Results and Provides Company Update
~ FDA granted priority review of BLA for ifezuntirgene inilparvovec (AMT-130) in Huntington’s diseas
Nov 2, 2026 Press
uniQure announced FDA acceptance and Priority Review of its BLA for ifezuntirgene inilparvovec (AMT-130), a gene…
Impact 7/10
Oct 30, 2026 Insider
Abi-Saab Walid was granted 18,750 shares
Chief Medical Officer
Sep 30, 2026 Inst.
MORGAN STANLEY · ADD
1,933,936 shares ($46.7M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
3 drugs tracked · Drug pipeline →
Upcoming
Recent

SecBot reports

35 filings · 3 press releases · 5 bullish · 5 bearish · 2 mixed · 23 neutral
All QURE filing & press-release reports (38)